Axicabtagene ciloleucel 40million-200million cells/68ml dispersion for infusion bags
Requires a prescription from a doctor or prescriber
Axicabtagene ciloleucel is an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Axicabtagene ciloleucel
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Axicabtagene ciloleucel
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
MHRA licensed products
View all licensed products for Axicabtagene ciloleucel on the MHRA register
Yescarta 40million-200million cells/68ml dispersion for infusion bags
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(14)
Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma (TA894)
Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy (TA895)
Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies (TA872)
Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments (TA927)
Non-Hodgkin lymphoma: diagnosis and management (NG52)
Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments (TA954)
Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after 2 or more lines of systemic treatment (TA1159)
Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma (TA677)
Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over (TA893)
Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma (TA649)
Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments (TA947)
Brentuximab vedotin in combination for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma (TA1059)
Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma (TA874)
Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after first-line chemoimmunotherapy when a stem cell transplant is suitable (TA1048)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 11 · 2017–2024
Showing the 50 most relevant studies, sorted by most relevant.
Nico Gagelmann, Michael R. Bishop, Francis Ayuk, et al.
Transplantation and Cellular Therapy, 2024
- Biological Products
- Cytokine Release Syndrome
- Receptors, Antigen, T-Cell
Jun Meng, Xiaoqin Wu, Zhen Sun, et al.
Frontiers in Oncology, 2021
Jason R. Westin, Olalekan O. Oluwole, Marie José Kersten, et al.
New England Journal of Medicine, 2023
- Antineoplastic Agents, Immunological
- Biological Products
- Lymphoma, Large B-Cell, Diffuse
Neelapu SS, Jacobson CA, Ghobadi A, et al.
2023
- Biological Products
- Lymphoma, Large B-Cell, Diffuse
- Receptors, Chimeric Antigen
Zhen Sun, RenDe Xun, Mengsi Liu, et al.
Frontiers in Immunology, 2021
- Receptors, Chimeric Antigen
- Glucocorticoids
- Lymphoma
Xiaoqin Wu, Xinyue Zhang, RenDe Xun, et al.
Frontiers in Immunology, 2021
- Biological Products
- Lymphoma
- Receptors, Antigen, T-Cell
Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett, et al.
New England Journal of Medicine, 2017
- Immunotherapy, Adoptive
- Interleukins
- Nervous System Diseases
Frederick L. Locke, Armin Ghobadi, Caron A. Jacobson, et al.
The Lancet Oncology, 2018
- Antineoplastic Combined Chemotherapy Protocols
- Biological Products
- Cyclophosphamide
Frederick L. Locke, David B. Miklos, Caron A. Jacobson, et al.
New England Journal of Medicine, 2021
- Immunotherapy, Adoptive
- Antineoplastic Agents, Immunological
- Receptors, Chimeric Antigen
Loretta J. Nastoupil, Michael D. Jain, Lei Feng, et al.
Journal of Clinical Oncology, 2020
- Progression-Free Survival
- Cytokine Release Syndrome
- Biological Products
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
Not available
Mechanism
The CD 19 antigen is an integral membrane glycoprotein normally expressed in B c…
Food interactions
None known
Human targets
1 target
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
14 days
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Axicabtagene ciloleucel was approved by the FDA on October 18th, 2017. It is marketed under the brand name Yescarta and is used to treat large B-cell lymphomas and follicular lymphoma in adults.[L40054] Axicabtagene ciloleucel was later approved by the EMA on August 23, 2018.[L42090]
[L40054]
In the US and Europe, it is used to treat adults with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.
[L40054][L42090]
Axicabtagene ciloleucel is also used to treat adults with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy in the US,[L40054] or three or more lines of systemic therapy in Europe.
[L42090]
Known interactions with other medications. Always consult a healthcare professional.
Showing 38 of 38 interactions
[L42090]
Axicabatagene ciloleucel is reported to induce cytokine release syndrome (CRS) and neurotoxicity. No carcinogenicity, genotoxicity, or reproductive toxicity studies have been conducted with axicabatagene ciloleucel.
[L40054]
Axicabtagene ciloleucel is a CD19-directed chimeric antigen receptor (CAR) T-cell therapy. It consists of genetically modified T cells of the patient receiving the immunotherapy. The manufacturing of axicabtagene ciloleucel begins with the collection of peripheral blood mononuclear cells from the patient, followed by the harvesting and genetic modification of T cells ex vivo. Retroviral transduction is used to express a CAR on T cells, creating anti-CD19 CAR T cells that are then expanded. Axicabtagene ciloleucel, a suspension of anti-CD19 CAR T cells, is infused back into the patient during treatment.[L40054] Axicabtagene ciloleucel is made up of two components: a single-chain variable fragment targets the CD19 proteins, and there are intracellular domains - CD28 and CD3-zeta co-stimulatory domains - that signal T-cell activation.[A249030][L40054] Once administered into the patient's bloodstream, axicabtagene ciloleucel recognizes the CD19-expressing target cells and the intracellular domains of the drug activate the downstream signalling cascades that lead to T-cell activation, proliferation, acquisition of effector functions, and secretion of inflammatory cytokines and chemokines that kill cancer cells.[L40054] Axicabtagene ciloleucel binds to CD19-expressing cancer cells and normal B cells.[L40054]
How the body processes this drug — absorption, distribution, metabolism, and elimination
[L40054]
The median peak level of anti-CD19 CAR T cells in the blood (Cmax) was 38.3 cells/µL (range: 0.8 to 1513.7 cells/μL), which decreased to a median of 2.1 cells/µL by one month (range: 0 to 167.4 cells/μL) and to a median of 0.4 cells/µL by three months (range: 0 to 28.4 cells/μL) after drug infusion.
[L42090]
Proteins and enzymes this drug interacts with in the body
PMID:29523808
Decreases the threshold for activation of downstream signaling pathways and for triggering B-cell responses to antigens .
PMID:1373518 PMID:16672701 PMID:2463100
Activates signaling pathways that lead to the activation of phosphatidylinositol 3-kinase and the mobilization of intracellular Ca(2+) stores .
PMID:12387743 PMID:16672701 PMID:9317126 PMID:9382888
Is not required for early steps during B cell differentiation in the blood marrow .
PMID:9317126
Required for normal differentiation of B-1 cells (By similarity). Required for normal B cell differentiation and proliferation in response to antigen challenges .
PMID:1373518 PMID:2463100
Required for normal levels of serum immunoglobulins, and for production of high-affinity antibodies in response to antigen challenge PMID:12387743 PMID:16672701 PMID:9317126
ATC L01XL03
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Axicabtagene ciloleucel
Additional database identifiers
DrugBank citations
If you use DrugBank data in your research, please cite the following publications: